Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shares were up 9.9% during mid-day trading on Wednesday . The stock traded as high as $4.50 and last traded at $4.44, approximately 4,745,848 shares changed hands during trading. A decline of 44% from the average daily volume of 8,469,285 shares. The stock had previously closed at $4.04.

Several research firms recently issued reports on ADAP. ValuEngine upgraded Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Thursday, November 7th. Finally, Zacks Investment Research raised Adaptimmune Therapeutics from a “sell” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $5.86.

The firm has a market capitalization of $470.06 million, a price-to-earnings ratio of -4.71 and a beta of 1.83. The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 0.15. The company’s fifty day moving average is $1.56 and its two-hundred day moving average is $1.75.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $7.00 million. On average, equities research analysts expect that Adaptimmune Therapeutics PLC – will post -1.37 EPS for the current year.

In other news, Director James Noble sold 300,000 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $4.67, for a total value of $1,401,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 317,323 shares of company stock worth $1,447,506. 22.36% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of ADAP. Tower Research Capital LLC TRC increased its stake in shares of Adaptimmune Therapeutics by 21,372.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 21,372 shares during the last quarter. Man Group plc raised its position in shares of Adaptimmune Therapeutics by 37.4% in the 2nd quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock valued at $7,394,000 after acquiring an additional 500,595 shares during the period. Millennium Management LLC raised its position in shares of Adaptimmune Therapeutics by 5.2% in the 3rd quarter. Millennium Management LLC now owns 914,416 shares of the biotechnology company’s stock valued at $1,380,000 after acquiring an additional 45,249 shares during the period. Finally, Bamco Inc. NY boosted its stake in Adaptimmune Therapeutics by 6.1% during the 2nd quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock worth $694,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 65.06% of the company’s stock.

Adaptimmune Therapeutics Company Profile (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Read More: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.